TNSN05257A1 - Beta-carbolines useful for treating inflammatory disease - Google Patents
Beta-carbolines useful for treating inflammatory diseaseInfo
- Publication number
- TNSN05257A1 TNSN05257A1 TNP2005000257A TNSN05257A TNSN05257A1 TN SN05257 A1 TNSN05257 A1 TN SN05257A1 TN P2005000257 A TNP2005000257 A TN P2005000257A TN SN05257 A TNSN05257 A TN SN05257A TN SN05257 A1 TNSN05257 A1 TN SN05257A1
- Authority
- TN
- Tunisia
- Prior art keywords
- beta
- inflammatory disease
- treating inflammatory
- useful
- carbolines
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46146803P | 2003-04-09 | 2003-04-09 | |
| PCT/US2004/011080 WO2004092167A1 (en) | 2003-04-09 | 2004-04-09 | Beta-carbolines useful for treating inflammatory disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN05257A1 true TNSN05257A1 (en) | 2007-07-10 |
Family
ID=33299818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2005000257A TNSN05257A1 (en) | 2003-04-09 | 2005-10-07 | Beta-carbolines useful for treating inflammatory disease |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7727985B2 (enExample) |
| EP (1) | EP1611134A1 (enExample) |
| JP (1) | JP2006522824A (enExample) |
| KR (1) | KR20060006031A (enExample) |
| CN (1) | CN1802375A (enExample) |
| AU (1) | AU2004230952A1 (enExample) |
| BR (1) | BRPI0409263A (enExample) |
| CA (1) | CA2521300A1 (enExample) |
| CO (1) | CO5700746A2 (enExample) |
| CR (1) | CR8042A (enExample) |
| EA (1) | EA009121B1 (enExample) |
| EC (1) | ECSP056145A (enExample) |
| HR (1) | HRP20050926A2 (enExample) |
| MA (1) | MA27837A1 (enExample) |
| MX (1) | MXPA05010793A (enExample) |
| NI (1) | NI200500174A (enExample) |
| NO (1) | NO20054598L (enExample) |
| OA (1) | OA13115A (enExample) |
| RS (1) | RS20050832A (enExample) |
| TN (1) | TNSN05257A1 (enExample) |
| WO (1) | WO2004092167A1 (enExample) |
| ZA (1) | ZA200508198B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006522824A (ja) | 2003-04-09 | 2006-10-05 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 炎症性疾患を処置するために有用なβ−カルボリン |
| JP2007532582A (ja) * | 2004-04-09 | 2007-11-15 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 炎症性疾患の処置に有用なβ−カルボリン |
| US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP1954290B1 (en) * | 2005-11-22 | 2012-07-25 | Merck Sharp & Dohme Corp. | Tricyclic compounds useful as inhibitors of kinases |
| US8426355B2 (en) * | 2006-03-15 | 2013-04-23 | Theralogics, Inc. | Methods of treating muscular wasting diseases using NF-κB activation inhibitors |
| WO2008002246A1 (en) * | 2006-06-28 | 2008-01-03 | Astrazeneca Ab | A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient. |
| WO2008076265A1 (en) * | 2006-12-13 | 2008-06-26 | Gilead Sciences, Inc. | MONOPHOSPHATES AS MUTUAL PRODRUGS OF ANTI-INFLAMMATORY SIGNAL TRANSDUCTION MODULATORS (AISTM'S) AND β-AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION |
| US20090137579A1 (en) * | 2007-10-23 | 2009-05-28 | Millennium Pharmaceuticals, Inc. | Mesylate salt of an IKK inhibitor |
| US20090131422A1 (en) * | 2007-10-23 | 2009-05-21 | Millennium Pharmaceuticals, Inc. | Salts of an IKK inhibitor |
| EP2297347B1 (en) | 2008-05-14 | 2017-03-08 | Millennium Pharmaceuticals, Inc. | Methods and kits for monitoring the effects of immunomodulators on adaptive immunity |
| KR101323448B1 (ko) | 2008-10-02 | 2013-11-27 | 아사히 가세이 파마 가부시키가이샤 | ８위 치환 이소퀴놀린 유도체 및 이의 용도 |
| US8748428B2 (en) | 2010-03-30 | 2014-06-10 | Novartis Ag | Use of a PKC inhibitor |
| DK2691394T3 (en) * | 2011-03-28 | 2017-08-28 | Sjt Molecular Res S L | RELATIONSHIPS FOR TREATMENT OF METABOLIC SYNDROME |
| CN102416014B (zh) * | 2011-09-13 | 2012-11-21 | 河南中医学院 | 一种生物碱类成分组合物在制备抗甲型h1n1流感病毒药物中的应用 |
| CN102391323B (zh) * | 2011-10-18 | 2013-09-25 | 首都医科大学 | 四氢-β-咔啉衍生物、其制备方法及其用途 |
| KR101646916B1 (ko) | 2015-07-13 | 2016-08-09 | 강원대학교산학협력단 | 베타-카르볼린 알칼로이드 화합물을 함유하는 염증성 질환의 예방 또는 치료용 조성물 |
| WO2017067670A1 (en) | 2015-10-23 | 2017-04-27 | Pharmathen S.A. | A novel process for the preparation of tryptamines and derivatives thereof |
| CN109593089B (zh) * | 2019-01-24 | 2022-01-28 | 西南大学 | 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用 |
| CN112824387B (zh) * | 2019-11-21 | 2023-03-21 | 济南尚博生物科技有限公司 | 一种2-甲基烟酸酯及其制备方法和应用 |
| CN117510494B (zh) * | 2023-11-07 | 2024-04-19 | 桂林医学院附属医院 | β-咔啉-沙利度胺偶联物及其在制备逆转ABT-199耐药的药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69925840T2 (de) | 1998-08-12 | 2006-05-04 | Pfizer Products Inc., Groton | Tace inhibitoren |
| DE19951360A1 (de) * | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
| CA2402549A1 (en) | 2000-03-15 | 2001-09-20 | Aventis Pharma Deutschland Gmbh | Substituted beta-carbolines |
| EP1268477B1 (en) * | 2000-03-15 | 2010-04-21 | Sanofi-Aventis Deutschland GmbH | Substituted beta-carbolines with ikb-kinase inhibiting activity |
| ES2286275T3 (es) | 2001-09-19 | 2007-12-01 | Pharmacia Corporation | Compuestos de pirazolo sustituidos para el tratamiento de la inflamacion. |
| DE60217532T8 (de) * | 2001-11-07 | 2008-02-07 | Millennium Pharmaceuticals, Inc., Cambridge | Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas |
| DE602004016127D1 (de) * | 2003-03-07 | 2008-10-09 | Lilly Co Eli | Antagonisten der opioidrezeptoren |
| JP2006522824A (ja) | 2003-04-09 | 2006-10-05 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 炎症性疾患を処置するために有用なβ−カルボリン |
-
2004
- 2004-04-09 JP JP2006509889A patent/JP2006522824A/ja active Pending
- 2004-04-09 EP EP04759390A patent/EP1611134A1/en not_active Withdrawn
- 2004-04-09 OA OA1200500279A patent/OA13115A/en unknown
- 2004-04-09 KR KR1020057019268A patent/KR20060006031A/ko not_active Ceased
- 2004-04-09 CN CNA2004800160170A patent/CN1802375A/zh active Pending
- 2004-04-09 BR BRPI0409263-5A patent/BRPI0409263A/pt not_active IP Right Cessation
- 2004-04-09 RS YUP-2005/0832A patent/RS20050832A/sr unknown
- 2004-04-09 HR HR20050926A patent/HRP20050926A2/hr not_active Application Discontinuation
- 2004-04-09 CA CA002521300A patent/CA2521300A1/en not_active Abandoned
- 2004-04-09 AU AU2004230952A patent/AU2004230952A1/en not_active Abandoned
- 2004-04-09 WO PCT/US2004/011080 patent/WO2004092167A1/en not_active Ceased
- 2004-04-09 US US10/821,545 patent/US7727985B2/en not_active Expired - Lifetime
- 2004-04-09 MX MXPA05010793A patent/MXPA05010793A/es active IP Right Grant
- 2004-04-09 EA EA200501584A patent/EA009121B1/ru not_active IP Right Cessation
-
2005
- 2005-10-06 NO NO20054598A patent/NO20054598L/no not_active Application Discontinuation
- 2005-10-07 NI NI200500174A patent/NI200500174A/es unknown
- 2005-10-07 TN TNP2005000257A patent/TNSN05257A1/en unknown
- 2005-10-11 ZA ZA200508198A patent/ZA200508198B/xx unknown
- 2005-10-12 CR CR8042A patent/CR8042A/es not_active Application Discontinuation
- 2005-11-04 CO CO05113041A patent/CO5700746A2/es not_active Application Discontinuation
- 2005-11-07 EC EC2005006145A patent/ECSP056145A/es unknown
- 2005-11-09 MA MA28592A patent/MA27837A1/fr unknown
-
2009
- 2009-12-17 US US12/640,335 patent/US20100093713A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20054598D0 (no) | 2005-10-06 |
| MXPA05010793A (es) | 2005-12-05 |
| CO5700746A2 (es) | 2006-11-30 |
| NO20054598L (no) | 2005-10-27 |
| MA27837A1 (fr) | 2006-04-03 |
| CA2521300A1 (en) | 2004-10-28 |
| EA009121B1 (ru) | 2007-10-26 |
| HRP20050926A2 (en) | 2006-06-30 |
| AU2004230952A1 (en) | 2004-10-28 |
| CR8042A (es) | 2006-05-30 |
| NI200500174A (es) | 2006-04-17 |
| OA13115A (en) | 2006-11-10 |
| WO2004092167A1 (en) | 2004-10-28 |
| BRPI0409263A (pt) | 2006-03-28 |
| EA200501584A1 (ru) | 2006-06-30 |
| JP2006522824A (ja) | 2006-10-05 |
| US20040235839A1 (en) | 2004-11-25 |
| US20100093713A1 (en) | 2010-04-15 |
| EP1611134A1 (en) | 2006-01-04 |
| ECSP056145A (es) | 2006-04-19 |
| CN1802375A (zh) | 2006-07-12 |
| RS20050832A (sr) | 2007-12-31 |
| US7727985B2 (en) | 2010-06-01 |
| WO2004092167A8 (en) | 2006-01-05 |
| KR20060006031A (ko) | 2006-01-18 |
| ZA200508198B (en) | 2007-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN05257A1 (en) | Beta-carbolines useful for treating inflammatory disease | |
| IL172942A0 (en) | Pyrazoloisoquinoline derivatives as kinase inhibitors | |
| IL260127B (en) | mek inhibitors and methods of using them | |
| NZ542616A (en) | P38 inhibitors and methods of use thereof | |
| TNSN07323A1 (en) | Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors | |
| MY142988A (en) | Novel aminobenzophenone compounds | |
| NO20050525L (no) | Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer | |
| PT2332940E (pt) | Azaindoles úteis como inibidores de jak e outras proteínas quinases | |
| NO20082594L (no) | Pyrimidinylbenzotiofenforbindelser | |
| NO20063479L (no) | Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer | |
| TW200508214A (en) | Novel compounds | |
| TW200510407A (en) | Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors | |
| AU2002358390A1 (en) | Novel compounds | |
| TW200700422A (en) | Compounds for inhibiting ksp kinesin activity | |
| TW200510427A (en) | Novel fused heterocycles and uses thereof | |
| TNSN06321A1 (en) | Beta-carbolines useful for treating inflammatory disease | |
| TW200505443A (en) | Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases | |
| TW200700066A (en) | Compounds for inhibiting ksp kinesin activity | |
| BR0318521A (pt) | arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados | |
| ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
| DE60316128D1 (de) | N-sulfonylurea-apoptosis-förderer | |
| MXPA03011167A (es) | Derivados de carbolina utiles como ihibidores de pdev. | |
| UA84016C2 (ru) | Бета-карболины, полезные для лечения воспалительных заболеваний, фармацевтическая композиция на их основе | |
| WO2003080624A3 (en) | Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases | |
| MXPA04004757A (es) | Uso de una ascomicina para el tratamiento de blefaritis. |